AIP
CADL icon

Ameritas Investment Partners’s Candel Therapeutics CADL Stock Holding History

Ameritas Investment Partners’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19.7K Hold
4,016
– – ﹤0.01% 2601
2025
Q4 		$22.7K Hold
4,016
– – ﹤0.01% 2576
2025
Q3 		$20.5K Hold
4,016
– – ﹤0.01% 2653
2025
Q2 		$20.3K Buy
4,016
+2,075
+107% +$10.7K ﹤0.01% 2655
2025
Q1 		$11K Hold
1,941
– – ﹤0.01% 2790
2024
Q4 		$16.8K Hold
1,941
– – ﹤0.01% 2700
2024
Q3 		$13.5K Hold
1,941
– – ﹤0.01% 2825
2024
Q2 		$12K Buy
+1,941
New +$14.6K ﹤0.01% 2858

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ameritas Investment Partners's CADL Position: Q1 2026 in Review

Ameritas Investment Partners held its Candel Therapeutics (CADL) position steady in Q1 2026 at 4,016 shares worth $19.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2601.

Ameritas Investment Partners first reported a position in CADL in Q2 2024 and has held it in 8 quarters since. The position peaked at $22.7K in Q4 2025. 114 funds tracked by Wall St. Rank hold CADL as of Q1 2026.

  • Ameritas Investment Partners held 4,016 shares of Candel Therapeutics worth $19.7K as of Q1 2026.
  • Ameritas Investment Partners left its Candel Therapeutics share count unchanged in Q1 2026.
  • Candel Therapeutics made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q1 2026, its #2601 holding.
  • Ameritas Investment Partners first reported a position in Candel Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • Ameritas Investment Partners's Candel Therapeutics position peaked at $22.7K in Q4 2025.
  • 114 funds tracked by Wall St. Rank held Candel Therapeutics as of Q1 2026.

Based on Ameritas Investment Partners's 13F filing for Q1 2026, filed 13 May 2026.